Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.
Department of Anaesthesiology and Intensive Care, Municipal Hospital in Zabrze-Biskupice, Zamkowa 4, 41-803 Zabrze, Poland.
Int J Mol Sci. 2024 Feb 3;25(3):1854. doi: 10.3390/ijms25031854.
Atherosclerosis stands out as one of the leading causes of global mortality. The inflammatory response against vascular wall components plays a pivotal role in the atherogenic process. The initiation of this process is notably driven by oxidized low-density lipoprotein (oxLDL) and a range of pro-inflammatory cytokines, with interleukin-1β (Il-1β) and tumor necrosis factor α (TNFα) emerging as particularly significant in the early stages of atherosclerotic plaque formation. In recent years, researchers worldwide have been diligently exploring innovative therapeutic approaches for metabolic diseases, recognizing their impact on the atherogenesis process. Our study aimed to investigate the influence of glucagon-like peptide 1 receptor agonists (GLP-1RA) on cytokine concentrations associated with the initiation of atherosclerotic plaque formation in a group of patients with type 2 diabetes and dyslipidemia. The study encompassed 50 subjects aged 41-81 (mean: 60.7), all diagnosed with type 2 diabetes, dyslipidemia and confirmed atherosclerosis based on B-mode ultrasound. Following a 180-day treatment with dulaglutide or semaglutide, we observed a statistically significant reduction in biochemical markers (oxLDL, TNFα and Il-1β) associated with the initiation of the atherosclerotic process ( < 0.001) within our study group. In addition to the already acknowledged positive effects of GLP-1RA on the metabolic parameters of treated patients, these drugs demonstrated a notable reduction in proinflammatory cytokine concentrations and may constitute an important element of therapy aimed at reducing cardiovascular risk.
动脉粥样硬化是全球主要死亡原因之一。血管壁成分的炎症反应在动脉粥样硬化过程中起着关键作用。该过程的启动主要由氧化型低密度脂蛋白（oxLDL）和一系列促炎细胞因子驱动，其中白细胞介素-1β（Il-1β）和肿瘤坏死因子α（TNFα）在动脉粥样硬化斑块形成的早期阶段尤为重要。近年来，全球研究人员一直在努力探索代谢疾病的创新治疗方法，认识到它们对动脉粥样硬化形成过程的影响。我们的研究旨在探讨胰高血糖素样肽 1 受体激动剂（GLP-1RA）对伴有 2 型糖尿病和血脂异常的患者群体中与动脉粥样硬化斑块形成启动相关的细胞因子浓度的影响。该研究纳入了 50 名年龄在 41-81 岁之间（平均：60.7 岁）的受试者，所有受试者均被诊断患有 2 型糖尿病、血脂异常，并通过 B 型超声证实患有动脉粥样硬化。在接受为期 180 天的度拉糖肽或司美格鲁肽治疗后，我们观察到研究组中与动脉粥样硬化过程启动相关的生化标志物（oxLDL、TNFα 和 Il-1β）显著降低（<0.001）。除了 GLP-1RA 对治疗患者代谢参数的已有公认的积极影响外，这些药物还显著降低了促炎细胞因子浓度，可能成为降低心血管风险治疗的重要组成部分。
